Book of Abstracts - Ruhr-Universität Bochum

Book of Abstracts - Ruhr-Universität Bochum Book of Abstracts - Ruhr-Universität Bochum

ruhrunibochum
from ruhrunibochum More from this publisher
19.11.2012 Views

P-31 ISBOMC `10 5.7 – 9.7. 2010 Ruhr-Universität Bochum Synthesis, Structures, Characterization and Biological Activities of Some Diorganotin(IV) Complexes See Mun Lee, *a H. Mohd. Ali, a and K. M. Lo a a University of Malaya, Faculty of Science, Department of Chemistry, 50603 Kuala Lumpur,Malaysia. E-mail: smlee@um.edu.my Metal complexes are widely prepared and have been successfully used in the treatment of numerous human diseases including cancer. Organotin(IV) complexes have been widely studied for their biological activities such as anticancer, antihistamine, antifungal and many others. Schiff base derived from substituted salicylaldehyde has been widely used as polydentate ligands in the preparation of metal complexes. In our present studies, a series of Schiff base ligands were prepared by reacting 3hydroxy-2-naphthoic hydrazide with substituted 2-hydroxyacetophenone. The diorganotin complexes were subsequently prepared by adding the ligands with diorganotin dichloride or oxide in 1:1 molar ratio and were characterized by various spectroscopic methods including IR, NMR spectroscopies. The X-ray structures of some of the diorganotin complexes namely {[1-(5-Bromo-2-oxidophenyl)ethylidene]-3-hydroxy-2-naphthohydrazidato}dimethyltin(IV) {[1-(5-Bromo-2 oxidophenyl)ethylidene]-3-hydroxy-2-naphtho-hydrazidato}dibutyltin(IV) {[1-(5-Chloro-2-oxidophenyl)ethylidene]-3-hydroxy-2-naphtho-hydrazidato}dimethyltin(IV) and {[1-(5-Chloro-2-oxidophenyl)ethylidene]-3-hydroxy-2-naphtho-hydrazidato}dimethyltin(IV) have been determined using single crystal X-ray diffractometry. The in vitro cytotoxic activity of the Schiff base ligands and diorganotin complexes has been evaluated against several cancer cell-lines such as HT-29, SKOV-3 and MCF7. References 1. M. Gielen, Coord. Chem. Rev. 1996, 151, 41-51. 2. A. J. Crowe, P. J. Smith, C. J. Cardin, H. E. Parge, F. E. Smith. Cancer Lett. 1984, 24 45-48. 89

P-32 ISBOMC `10 5.7 – 9.7. 2010 Ruhr-Universität Bochum Organometallic Iridium Anticancer Complexes Zhe Liu, Abraha Habtemariam, Ana Pizarri, Sally Fletcher, Guy Clarkson and Peter J. Sadler Department of Chemistry, University of Warwick, Coventry CV4 7AL, U.K. E-mail: Z.Liu.2@warwick.ac.uk Cisplatin has been used to treat various types of cancers for over 30 years, however, a number of serious side-effects of cisplatin have stimulated the long quest for other metal-based anticancer agents, especially drugs which possess a wider range of anticancer activity and with fewer side effects than cisplatin. There is much current interest in the design of ruthenium 1 and osmium 2 complexes as anticancer agents, but only a small amount of work has been done to investigate the antitumour activity of iridium complexes. 3 Here we report the synthesis and characterization of a wide range of Ir(III) cyclopentadienyl complexes. We have studied their solid state structures, hydrolysis rates, reactivity towards nucleobases and acidity of aqua complexes. Their cell uptake and distribution and toxicity towards cancer cells have been studied and correlated with their chemical properties. Both the chemical and biological activity of these complexes show a strong dependence on the nature of the substituents on the cyclopentadienyl and the other ligands in the complexes. Acknowledgements: We thank WPRS (scholarship for Z.L), ERC (award for P.J.S.), EDRF and AWM for Science City funding, and members of COST Action D39 for stimulating discussions. References 1. (a) A. Habtemariam, M. Melchart, R. Fernndez, S. Parsons, I. D. H. Oswald, A. Parkin, F. P. A. Fabbiani, J. E. Davidson, A. Dawson, R. E. Aird, D. I. Jodrell, P. J. Sadler, J. Med. Chem., 2006, 49, 6858-6868. (b) J. M. Redemaker-Lakhai, D. van den. Bongard, D. Pluim, J. H. Beijnen, J. H. M. Schellens, Clin. Cancer Res. 2004, 10, 3717–3727. (c) I. Bratsos, S. Jedner, T. Gianferrara, E. Alessio, Chimia 2007, 61, 692-697. 2. (a) A. F. A. Peacock, S. Parsons, P. J. Sadler, J. Am. Chem. Soc. 2007, 129, 3348-3357. (b) P.C. A. Bruijnincx and P. J. Sadler, Adv. Inorg. Chem. 2009, 61, 1-62. 3. S. Schäfer, I. Ott, R. Gust, W. S. Sheldrick, Eur. J. Inorg. Chem. 2007, 3034-3046. 90

P-31<br />

ISBOMC `10 5.7 – 9.7. 2010 <strong>Ruhr</strong>-<strong>Universität</strong> <strong>Bochum</strong><br />

Synthesis, Structures, Characterization and Biological Activities <strong>of</strong> Some<br />

Diorganotin(IV) Complexes<br />

See Mun Lee, *a H. Mohd. Ali, a and K. M. Lo a<br />

a University <strong>of</strong> Malaya, Faculty <strong>of</strong> Science, Department <strong>of</strong> Chemistry, 50603 Kuala Lumpur,Malaysia.<br />

E-mail: smlee@um.edu.my<br />

Metal complexes are widely prepared and have been successfully used in the treatment <strong>of</strong> numerous<br />

human diseases including cancer. Organotin(IV) complexes have been widely studied for their<br />

biological activities such as anticancer, antihistamine, antifungal and many others. Schiff base derived<br />

from substituted salicylaldehyde has been widely used as polydentate ligands in the preparation <strong>of</strong><br />

metal complexes. In our present studies, a series <strong>of</strong> Schiff base ligands were prepared by reacting 3hydroxy-2-naphthoic<br />

hydrazide with substituted 2-hydroxyacetophenone. The diorganotin complexes<br />

were subsequently prepared by adding the ligands with diorganotin dichloride or oxide in 1:1 molar<br />

ratio and were characterized by various spectroscopic methods including IR, NMR spectroscopies.<br />

The X-ray structures <strong>of</strong> some <strong>of</strong> the diorganotin complexes namely<br />

{[1-(5-Bromo-2-oxidophenyl)ethylidene]-3-hydroxy-2-naphthohydrazidato}dimethyltin(IV)<br />

{[1-(5-Bromo-2 oxidophenyl)ethylidene]-3-hydroxy-2-naphtho-hydrazidato}dibutyltin(IV)<br />

{[1-(5-Chloro-2-oxidophenyl)ethylidene]-3-hydroxy-2-naphtho-hydrazidato}dimethyltin(IV) and<br />

{[1-(5-Chloro-2-oxidophenyl)ethylidene]-3-hydroxy-2-naphtho-hydrazidato}dimethyltin(IV)<br />

have been determined using single crystal X-ray diffractometry. The in vitro cytotoxic activity <strong>of</strong> the<br />

Schiff base ligands and diorganotin complexes has been evaluated against several cancer cell-lines<br />

such as HT-29, SKOV-3 and MCF7.<br />

References<br />

1. M. Gielen, Coord. Chem. Rev. 1996, 151, 41-51.<br />

2. A. J. Crowe, P. J. Smith, C. J. Cardin, H. E. Parge, F. E. Smith. Cancer Lett. 1984, 24 45-48.<br />

89

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!